Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $64.17 Average PT from Brokerages

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have been given an average recommendation of “Buy” by the eight brokerages that are currently covering the company, MarketBeat reports. Eight investment analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have issued a report on the stock in the last year is $64.17.

JSPR has been the topic of a number of research reports. Royal Bank of Canada initiated coverage on shares of Jasper Therapeutics in a research report on Thursday, March 28th. They set an “outperform” rating and a $70.00 target price on the stock. Oppenheimer restated an “outperform” rating and set a $80.00 target price on shares of Jasper Therapeutics in a research report on Thursday, March 7th. TD Cowen initiated coverage on shares of Jasper Therapeutics in a research report on Monday, March 18th. They set an “outperform” rating on the stock. Finally, Evercore ISI initiated coverage on Jasper Therapeutics in a research note on Wednesday, April 3rd. They issued an “outperform” rating and a $65.00 price target for the company.

Jasper Therapeutics Stock Up 8.9 %

Shares of NASDAQ JSPR opened at $23.87 on Friday. Jasper Therapeutics has a 12-month low of $4.00 and a 12-month high of $31.01. The company has a market cap of $359.48 million, a price-to-earnings ratio of -3.85 and a beta of 2.21. The firm’s 50-day simple moving average is $25.06 and its 200 day simple moving average is $14.37.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Monday, March 4th. The company reported ($1.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.65) by $0.15. On average, equities analysts expect that Jasper Therapeutics will post -5 earnings per share for the current year.

Insider Activity

In other Jasper Therapeutics news, major shareholder Velan Capital Investment Manag bought 350,000 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was acquired at an average cost of $12.95 per share, with a total value of $4,532,500.00. Following the purchase, the insider now owns 1,188,500 shares in the company, valued at $15,391,075. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.90% of the stock is currently owned by company insiders.

Institutional Trading of Jasper Therapeutics

A number of large investors have recently bought and sold shares of JSPR. Ieq Capital LLC bought a new stake in Jasper Therapeutics during the 4th quarter worth approximately $43,000. Summit Trail Advisors LLC bought a new stake in Jasper Therapeutics during the 3rd quarter worth approximately $46,000. Forefront Analytics LLC grew its stake in shares of Jasper Therapeutics by 59.7% during the 3rd quarter. Forefront Analytics LLC now owns 110,792 shares of the company’s stock worth $78,000 after acquiring an additional 41,425 shares in the last quarter. Cowen AND Company LLC bought a new position in shares of Jasper Therapeutics during the 3rd quarter worth approximately $140,000. Finally, Monaco Asset Management SAM bought a new position in shares of Jasper Therapeutics during the 4th quarter worth approximately $197,000. 79.85% of the stock is owned by institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.